Proteostasis Therapeutics Wins Big With FDA Decision
Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares made a solid gain on Wednesday after a key U.S. Food and Drug Administration (FDA)...
Many CF Patients Have Long-term Staphylococcus Aureus Infections, Study Shows
Many cystic fibrosis patients have long-term Staphylococcus aureus infections, with the bacteria’s resistance to antibiotics fluctuating...
GeneFo Releases Updated 2018 Guide to Help Cystic Fibrosis Patients Navigate Treatment Options
GeneFo has put together an updated 2018 guide on treatment options for people with cystic fibrosis (CF) after recent developments again...
Proteostasis Therapeutics' FDA Breakthrough Therapy Designation Gives It An Edge
Summary * Proteostasis Therapeutics obtains breakthrough therapy designation from the FDA based on positive data from a phase 2 trial...
Airway Abnormality, Immunodeficiency Are Key Causes of Non-CF Bronchiectasis in Turkey, Study Finds
The most common causes of non-cystic fibrosis bronchiectasis in Turkish children are an airway abnormality called primary ciliary...
Eluforsen for cystic fibrosis
ProQR is developing an investigational product, eluforsen (QR-010) for people with cystic fibrosis (CF) that have the F508del mutation....
Staphylococcus aureus in Patients Diagnosed With Bronchiectasis Without Cystic Fibrosis
Patients diagnosed with bronchiectasis and in whom sputum cultures grow Staphylococcus aureus may not experience a difference in...
Early Growth Patterns Affect CF Children’s Lung Function at Age 12, Study Shows
Children with cystic fibrosis who are able to recover from below-normal growth in their first two years are more likely to achieve normal...
Vertex’s VX-659 Triple Combo To Be Tested in Phase 3 Trial in Patients with 2 Copies of F508del Muta
Vertex Pharmaceuticals is launching a new Phase 3 trial to assess the triple combination of VX-659 plus tezacaftor (VX-661) and Kalydeco...
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Pati
RPL554 demonstrates a favorable pharmacokinetic and pharmacodynamic profile in cystic fibrosis patients LONDON, UK I March 02, 2018 I...
